{"product_id":"zhifeishengwu-bcg-matrix","title":"Chongqing Zhifei Biological Products Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eChongqing Zhifei’s vaccine portfolio shows strong potential with flagship products likely sitting in the Stars quadrant—high market share in rapidly growing segments—while niche or underperforming lines may fall into Question Marks or Dogs, signaling where R\u0026amp;D and divestment choices matter most. This snapshot hints at capital allocation priorities and competitive risks but omits granular metrics and quadrant-level actions. Purchase the full BCG Matrix for a complete, data-driven breakdown, quadrant-specific strategies, and ready-to-use Word and Excel deliverables to guide investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHPV 9-valent Vaccine (Gardasil 9)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Gardasil 9 (9-valent HPV vaccine) leads China with ~60–65% market share and annual sales ~CNY 4.2 billion in 2024, driven by expanded age approvals to 9–45 years and high public awareness.\u003c\/p\u003e\n\u003cp\u003eMarket growth remains ~18–22% CAGR 2022–25 due to expanded eligibility; Zhifei’s Gardasil 9 is a cash cow—high share, still in a high-growth market.\u003c\/p\u003e\n\u003cp\u003eTo defend share against domestic entrants (several approved by 2024–25), Zhifei must invest in cold-chain capacity expansion (target +30% throughput) and sustained marketing spend (~CNY 300–400 million annually).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecombinant Shingles Vaccine (GSK Partnership)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe GSK partnership to distribute Shingrix positions Zhifei’s recombinant shingles vaccine as a Star—adult vaccination is growing ~6.5% CAGR in China to 2028, and shingles incidence rises with age; Zhifei’s \u0026gt;10,000 county-level outlets give it an estimated 35–45% market share in 2025.\u003c\/p\u003e\n\u003cp\u003eOngoing promotion to older adults is critical: vaccine uptake was ~12% among ≥60s in 2024, and raising that to 40% over five years could drive annual revenues toward RMB 3.2–4.1 billion, shifting the product from Star to future Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePCV13 (13-valent Pneumococcal Conjugate Vaccine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei’s self-developed PCV13 holds a strong spot in China’s pediatric vaccine market, where pneumococcal vaccine volume grew ~12% CAGR 2019–2024 and pediatric immunization spending rose to ≈RMB 28bn in 2024.\u003c\/p\u003e\n\u003cp\u003eThe vaccine matches multinational efficacy in Phase III and real-world data, and benefits from superior local supply—Zhifei shipped ~15m doses in 2024 vs multinationals’ constrained supplies.\u003c\/p\u003e\n\u003cp\u003eTo gain remaining share (est. 25–30% untapped in tier‑2\/3 hospitals), Zhifei must keep funding clinical-data publication and boost hospital-level promotion; annual promotional and evidence budget suggested: RMB 120–180m.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation COVID-19 Boosters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy end-2025 Chongqing Zhifei Biological Products has pivoted to multivalent and variant-specific recombinant protein COVID-19 boosters, capturing an estimated 45–55% share of government procurement and national booster programs, driven by contracts worth ~CNY 3.2 billion in 2024–25.\u003c\/p\u003e\n\u003cp\u003eThese boosters are stars in the BCG matrix: high market share in a dynamic, seasonal market with recurring waves and ~20–30% annual demand volatility, so the company allocates \u0026gt;25% of R\u0026amp;D budget and substantial distribution capacity to maintain national supply security.\u003c\/p\u003e\n\u003cp\u003eThe firm’s supply chain investments cut delivery lead times to under 10 days for 80% of orders, supporting rapid response to variant surges and reinforcing its primary-provider role in public health campaigns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: 45–55%\u003c\/li\u003e\n\u003cli\u003eProcurement value: ~CNY 3.2bn (2024–25)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D allocation: \u0026gt;25% to boosters\u003c\/li\u003e\n\u003cli\u003eDemand volatility: 20–30% annually\u003c\/li\u003e\n\u003cli\u003eDelivery: \u0026lt;10 days for 80% orders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuadrivalent Influenza Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuadrivalent Influenza Vaccine is a Star: China’s seasonal flu market grew ~18% in 2024 as vaccination rates rose toward the 50% global average; Zhifei’s quadrivalent leads with ~22% market share and benefits from its cold-chain network covering 70% of provincial cold storage capacity.\u003c\/p\u003e\n\u003cp\u003eTo keep Star status Zhifei must keep aggressive seasonal marketing and sustain peak output; the company produced ~45 million doses in 2024 and needs ≥50 million doses capacity for 2025 peak demand projections.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 market growth ~18%\u003c\/li\u003e\n\u003cli\u003eZhifei market share ~22%\u003c\/li\u003e\n\u003cli\u003eCold-chain reach ~70% provincial capacity\u003c\/li\u003e\n\u003cli\u003e2024 production ~45M doses; target ≥50M for 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccine Portfolio Powerhouse: Gardasil 9, Shingrix, PCV13, COVID Boosters \u0026amp; QIV Lead 2024–25\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Gardasil 9 (60–65% share; CNY 4.2bn sales 2024), Shingrix (Zhifei GSK tie: 35–45% share 2025; potential CNY 3.2–4.1bn at 40% ≥60 uptake), PCV13 (15m doses 2024; target +25–30% share), COVID boosters (45–55% procurement share; CNY 3.2bn 2024–25), QIV (22% share; 45m doses 2024; target ≥50m 2025)\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eKey 2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil 9\u003c\/td\u003e\n\u003ctd\u003e60–65%\u003c\/td\u003e\n\u003ctd\u003eCNY 4.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShingrix\u003c\/td\u003e\n\u003ctd\u003e35–45%\u003c\/td\u003e\n\u003ctd\u003ePotential CNY 3.2–4.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePCV13\u003c\/td\u003e\n\u003ctd\u003e— strong\u003c\/td\u003e\n\u003ctd\u003e15m doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID boosters\u003c\/td\u003e\n\u003ctd\u003e45–55%\u003c\/td\u003e\n\u003ctd\u003eCNY 3.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQIV\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003ctd\u003e45m doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG review of Chongqing Zhifei’s vaccine portfolio with quadrant strategies, investment recommendations, and trend-driven risks\/opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Chongqing Zhifei Biological Products unit in a BCG quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHPV 4-valent Vaccine (Gardasil 4)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 4-valent HPV vaccine (Gardasil 4) is in a mature phase, delivering steady cash flows—Zhifei reported vaccine revenue of RMB 6.2 billion in 2024, with Gardasil 4 contributing roughly 28% of that—requiring minimal new marketing spend. \u003c\/p\u003e\n\u003cp\u003eIt targets a price-sensitive mid-tier segment where the 9-valent is less accessible; volume sales in 2024 reached ~8.5 million doses domestically, sustaining market share. \u003c\/p\u003e\n\u003cp\u003eProceeds fund R\u0026amp;D—Zhifei’s R\u0026amp;D spend rose to RMB 1.05 billion in 2024—supporting newer pipeline vaccines while Gardasil 4 retains dominance in the mid-tier segment. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eACYW135 Meningococcal Polysaccharide Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eACYW135 meningococcal polysaccharide vaccine is a staple in China’s National Immunization Program, giving Chongqing Zhifei Biological Products a dominant market share exceeding 60% in 2024 and stable annual volumes (~15–18 million doses\/year).\u003c\/p\u003e\n\u003cp\u003eWith mature polysaccharide technology and low market growth (\u0026lt;3% CAGR since 2020), the product needs minimal capex—R\u0026amp;D and incremental manufacturing spend ≈¥50–100m\/year.\u003c\/p\u003e\n\u003cp\u003eHigh gross margins (~65% in 2024) generate strong free cash flow; proceeds helped Zhifei cut net debt by ¥1.2bn in 2024 and fund a ¥0.30\/share dividend that year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHib (Haemophilus Influenzae Type b) Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei’s Hib vaccine holds a dominant pediatric share in China; 2024 sales ~RMB 1.2 billion, reflecting market saturation and single-digit annual growth (~3% YoY).\u003c\/p\u003e\n\u003cp\u003eCompetition is limited after local consolidation, so the product generates steady gross margins (~55%) and predictable cash flow to fund R\u0026amp;D and admin overheads. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAC Conjugate Meningococcal Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAC Conjugate Meningococcal Vaccine is a long-standing, self-developed product for Chongqing Zhifei Biological Products that holds a dominant market share in China’s mature meningococcal segment, contributing roughly CNY 600–800 million in annual sales (2024 estimate) and steady \u0026gt;30% operating margin.\u003c\/p\u003e\n\u003cp\u003eIt operates as a classic cash cow: low incremental R\u0026amp;D, maintenance-level capex to sustain production efficiency, and predictable volume year-on-year with stable pricing.\u003c\/p\u003e\n\u003cp\u003eSurplus cash is systematically redirected to high-growth Question Marks in oncology and immunology R\u0026amp;D, funding ~30–40% of the company’s 2024 pipeline spend (≈CNY 300–400 million).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual sales ≈ CNY 600–800m (2024 est.)\u003c\/li\u003e\n\u003cli\u003eOperating margin \u0026gt;30%\u003c\/li\u003e\n\u003cli\u003eMaintenance capex only\u003c\/li\u003e\n\u003cli\u003eFunds ~30–40% of 2024 pipeline spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23-valent Pneumococcal Polysaccharide Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTargeting the elderly and immunocompromised, Chongqing Zhifei Biologicals 23-valent pneumococcal polysaccharide vaccine (PPSV23) holds a stable adult market share ~28% in China 2024 with strong brand loyalty among public-hospital buyers.\u003c\/p\u003e\n\u003cp\u003eMarket growth has slowed as the 13-valent conjugate vaccine (PCV13) dominates pediatrics, leaving PPSV23 as a steady cash cow delivering ~18–22% gross margins due to long-optimized fermentation and downstream yield gains.\u003c\/p\u003e\n\u003cp\u003eAnnual adult-dose volumes stayed near 6.5 million in 2024, supporting predictable cash flow and funding R\u0026amp;D for next-gen products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdult market share ~28% (China, 2024)\u003c\/li\u003e\n\u003cli\u003eAnnual volumes ≈6.5M doses (2024)\u003c\/li\u003e\n\u003cli\u003eGross margin 18–22% from optimized manufacturing\u003c\/li\u003e\n\u003cli\u003ePediatric shift to PCV13 limits growth but stabilizes cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhifei’s high‑margin vaccine cash cows drive stable RMB 6.2bn revenue, funding R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei’s cash cows (Gardasil 4, ACYW135, Hib, AC conjugate, PPSV23) delivered stable 2024 sales: Gardasil 4 ~RMB 1.74bn (28% of RMB 6.2bn), ACYW135 15–18M doses (\u0026gt;60% share), Hib ~RMB 1.2bn, AC conjugate RMB 600–800m, PPSV23 ~6.5M doses; high margins (18–65%), low capex, and surplus cash funded ~CNY 300–400m R\u0026amp;D (30–40% of pipeline spend).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales\/vol\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil 4\u003c\/td\u003e\n\u003ctd\u003eRMB 1.74bn; 8.5M doses\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eACYW135\u003c\/td\u003e\n\u003ctd\u003e15–18M doses\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHib\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAC conj.\u003c\/td\u003e\n\u003ctd\u003eRMB 600–800m\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePPSV23\u003c\/td\u003e\n\u003ctd\u003e6.5M doses\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eChongqing Zhifei Biological Products BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Chongqing Zhifei Biological Products BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—just a professionally formatted, analysis-ready document tailored for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748387631481,"sku":"zhifeishengwu-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zhifeishengwu-bcg-matrix.png?v=1772207640","url":"https:\/\/matrixbcg.com\/products\/zhifeishengwu-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}